The Effect of Selenium Supplementation Among Pediatric Patients With Burns

Burns Clinical Trial

Official title:

The Effect of Selenium Supplementation Among Pediatric Patients With Burns

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00860379
• Other study ID #: 2007-P-001176
• Status: Terminated
• Phase: Phase 4
• Start date: January 2009
• Est. completion date: December 2019

Study information

• Verified date: July 2021
• Source: Shriners Hospitals for Children
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The selenium status of children with major burns is suboptimal which may increase the incidence of infection. Se requirements during critical illness are not known. Results from this investigation may provide a tool for recommending Se supplements during burn injury.

The hypothesis of this research is that Se supplementation will restore the depressed Se status among children with burn injuries. The secondary hypothesis is that Se status is related to the incidence of infection among pediatric patients with burns.

Description:

Study Title: The effect of selenium supplementation among pediatric patients with burns

Primary Investigator: Maggie L. Dylewski, PhD, RD

Co-investigators: RL. Sheridan, MD; C Ryan, MD; K Prelack, PhD,RD; M Lydon, RN; J Weber, RN, BSN, CIC

Approved by: FDA (IND # 78963), Partners IRB (#2007-P-001176).

Funding: private grant from the Boston Burn Foundation

Background Information: Selenium, an essential dietary nutrient, is a component of glutathione peroxidase (an antioxidant) and thioredoxin reductase, an enzyme that regulates cytokine expression and thus plays a role in the immune system. Previous studies among adult burn patients showed that IV selenium supplementation was related to decreased infection and mortality. Please refer to the study protocol for further details.

Previous Research: We previously showed that children with burns (n = 20) > 20% TBSA had low plasma selenium values compared to reference data of healthy American children. Results from this study also found a significant relationship between plasma selenium and incidence of infections.

Study Design: Randomized, double-blind, placebo-controlled clinical trial

Specific Aims:

1. to determine the impact of supplemental selenium on plasma selenium, glutathione peroxidase activity, and urine selenium among pediatric patients with burns >20% total body surface area (TBSA) burn.

2. to determine the association between selenium supplementation, biomarkers of Se status and indicators of stress and infection.

Subjects: N = 75 pediatric patients with burns.

Inclusion criteria:

• Between 1 and 18 years of age admitted to Shriners Burns Hospital

• TBSA burn of > 20%

• Existing IV catheter

• Enrolled into study within 3 weeks of burn injury

Treatment:

All subjects will be randomized into 1 of 3 groups and receive the treatment for 8 weeks, until 95% wound closure, or until central venous catheter access is discontinued.

1. Placebo (IV 0.9% sodium chloride)

2. 2 mcg/kg/day IV Selenium

3. 4 mcg/kg/day IV Selenium

Biological sample collection:

• 4 mL or 8 mL (8 every other week) of plasma once a week

• 24-hour urine collection once a week

Sample analyses:

• Samples will be frozen until analyses

• Samples will be sent to the outside lab for analyses.

• Plasma will also be sent to Massachusetts General Hospital every other week for plasma selenium analysis (to assess for toxicity)

Primary outcome measures:

• Plasma selenium

• Plasma glutathione peroxidase

• Urine selenium

Secondary outcome measures:

• occurrence of pneumonia or infection (bacterial or fungal) in the wound, blood, or urine

Risks:

• Supplement doses were determined using data from previous studies, current recommended dietary allowance (RDA) and upper tolerable limits, American Society for Parenteral and Enteral Nutrition (ASPEN) guidelines for parenteral selenium, and dietary data recorded from our previous study. According to reference weights (NHANES III) supplement doses do not exceed the upper tolerable limits for children.

• Selenium toxicity is rare. However plasma will be assessed every other week for selenium levels.

Monitoring and Quality Assurance:

• All subjects will be monitored for any treatment-related adverse events for 2 weeks following discontinuation of the study therapy

• Any adverse events will be reported to the Partners Human Research Committee and the FDA per the guidelines.

An independent Data Safety Monitoring Board, consisting of 4 knowledgeable staff members, will meet 2 times per year to monitor the data for safety.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 14
• Est. completion date: December 2019
• Est. primary completion date: December 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Year to 18 Years

Eligibility

Inclusion Criteria:

• Between 1 and 18 years of age admitted to Shriners Burns Hospital

• TBSA burn of > 20%

• Existing IV catheter

• Enrolled into study within 3 weeks of burn injury

Exclusion Criteria:

• < 1 year or > 18 years of age

• < 20% TBSA burn

• No existing IV catheter

• Pre-existing or acute renal disease (creatine > 1.5 mg/dl)

• Pre-existing or acute liver disease (bilirubin > 3)

• Pre-existing or acute thyroid disorders

• Cancer

• AIDS

• Pregnancy (as determined by routine admission labs)

Related Conditions & MeSH terms

• Burns

Intervention

Drug:
• Selenium1
2 ug/kg
• Selenium2
4 ug/kg
• Placebo
IV saline as placebo

Locations

Country	Name	City	State
United States	Shriners Hospitals for Children	Boston	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Shriners Hospitals for Children

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Plasma Selenium	plasma selenium of all subjects was assessed	Average plasma selenium calculated over 8 weeks, assessed weekly.